CLOVER-1 and CLOVER-WaM: A phase 2 trial looking at the medication iopofosine I 131 (CLR 131) in people with B-cell lymphomas and an expansion in Waldenstrom Macroglobulinaemia (WM)

This multi-centre trial is evaluating the medication iopofosine I 131 (CLR 131) in people with certain B cell malignancies that have either not responded to treatment (refractory) or have come back after treatment (relapsed). There is then a further phase looking specifically at Waldenstrom Macroglobulinaemia (WM)

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT02952508

Trial aim and background  

The aim of this trial is to find out the effectiveness of the medication CLR 131 in B cell lymphomas. The first part of the trial is studying it in people with relapsed or refractory disease. The second part of the trial is evaluating the IV administration of CLR 131 in patient with WM who have failed to respond to at least two therapies. 

CLR 131 is a targeted radiotherapeutic that is taken up by cancer cells and has been shown to work well in eliminating tumours. There is currently an unmet need for effective agents with new mechanisms of action in B cell malignancies, hence this trial. Treating people with refractory or relapsed WM can be particularly challenging which is why there is the expansion phase.

Who can enter

People aged over 18 with refractory or relapsed B cell lymphomas may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • University College London Hospitals, London
  • Glasgow

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT02952508

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.